XOLAIR 150 mg, solution for injection in a pre-filled syringe syringe, 1 ml, CIP 3400930281130
Active ingredients: Omalizumab
Commercialized according to BDPMDispensing in France: Prescription only
Solution for injectionsyringe, 1 ml, CIP 3400930281130sous-cutanée
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- XOLAIR 150 mg, solution injectable en seringue préremplie
- Pharmaceutical form
- solution injectable
- Route of administration
- sous-cutanée
- Presentation description
- 1 seringue(s) préremplie(s) en verre de 1 ml avec une aiguille sertie de calibre 27 gauge dans une plaquette thermoformée
- Marketing authorisation holder
- NOVARTIS EUROPHARM (IRLANDE)
- Reimbursement according to BDPM
- 65 %
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 21 Oct 2024
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Prescribed by specialists only
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
61971520CIP73028113CIP133400930281130Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| OMALIZUMABsolution | 150 mg · une seringue préremplie de 1 mL | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Other packages of this medicine
The same medicine in another pack size, according to BDPM.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.